Shares in Stratagene rose 28.8 percent for the four-day trading week ended Tuesday after Agilent signed a deal to buy the firm for $10.94 a share (see related article this issue). The acquisition price represents a 28 percent premium over Stratagene’s closing price the day before the deal was announced.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.

Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.

The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.

In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.